S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Standardizing Immune-Related Adverse Event Protocols in Oncology

As immunotherapy reshapes the oncology landscape, the emergence of complex immune-related adverse events poses a persistent challenge to patient safety and trial continuity. On August 4, 2026, industry experts will convene to address the necessity of standardized grading and cross-functional coordination in managing these unique clinical complications.

Standardizing Immune-Related Adverse Event Protocols in Oncology
Photo: Bio & News

The upcoming webinar, hosted by Xtalks, focuses on the critical intersection of patient retention and proactive safety management. Dr. Gwyn Bebb, SVP and Head of Medical Affairs at Premier Research, will join Senior Medical Director Salini Naidu to explore how rigorous site training and standardized guidelines can mitigate risks associated with immune-based therapies.

Effective management of these events requires seamless collaboration between sponsors, medical monitors, and investigative sites. The session aims to provide actionable strategies for improving trial execution, ensuring that promising oncology assets remain viable while maintaining the highest standards of participant care. The live event is scheduled for 11am EDT, offering a platform for professionals to refine their approach to the evolving demands of oncology research.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!